Pravastatin
HMG-CoA Reductase Inhibitor (Statin)
NADAC/unit
$0.0600
No Shortage
Tier 1: 290.6%
12 Manufacturers
47 ANDAs
Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyper....
Active Shortages
2025-06-13 Shortage reported, Teva Pharmaceuticals USA, Inc.
2025-06-13 Shortage reported, Teva Pharmaceuticals USA, Inc.
2025-06-13 Shortage reported, Teva Pharmaceuticals USA, Inc.
2025-06-13 Shortage reported, Teva Pharmaceuticals USA, Inc.
2025-06-13 Shortage reported, Teva Pharmaceuticals USA, Inc.
Market Intelligence
2025-04-16 Class II Recall: Glenmark Pharmaceuticals Inc., USA
2025-04-16 Class II Recall: Glenmark Pharmaceuticals Inc., USA
2025-04-16 Class II Recall: Glenmark Pharmaceuticals Inc., USA
2025-04-16 Class II Recall: Glenmark Pharmaceuticals Inc., USA
2024-07-24 Class II Recall: Glenmark Pharmaceuticals Inc., USA
Generic Manufacturers
ACCORD HEALTHCARE INCAPOTEX INCAUROBINDO PHARMA LTDAUROBINDO PHARMA USA INCBIOCON PHARMA INCCHARTWELL RX SCIENCES LLCCIPLA LTDDR REDDYS LABORATORIES INCGLENMARK PHARMACEUTICALS LTDSENORES PHARMACEUTICALS INCWATSON LABORATORIES INCZYDUS PHARMACEUTICALS USA INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.